Literature DB >> 159863

Restoration of impaired immune functions of aged animals by chronic bestatin treatment.

M Bruley-Rosset, I Florentin, N Kiger, J Schulz, G Mathé.   

Abstract

An attempt to correct the state of immunodeficiency in old age was made by repeatedly injecting a chemically defined immunostimulating agent, bestatin, to 16 month old (C57Bl/6 x BALB/c) F1 mice. Aged mice were found to have depressed T-cell and B-cell responses but increased ADCC activity. Weekly injections of bestatin over a period of 6 months resulted in varying effects depending on the dose administered. Small doses (10 microgram per injection) were more effective in restoring humoral responses to SRBC rather than delayed-type hypersensitivity reactions, whereas large doses (100 microgram per injection) acted in the opposite way. Macrophage activation was only obtained after the administration of the high doses of bestatin. Continuous treatment with bestatin did not prevent the appearance of suppressor cells induced by ageing. It led to a significant reduction of ADCC activity in aged animals near to the base line value of young animals. Animals were examined for the presence of spontaneous tumours from the end of the treatment until the age of 28 months. A significant reduction of spontaneous tumour incidence was observed in mice given repeated injections of 100 microgram bestatin when compared to untreated aged mice and to mice given the low doses of bestatin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 159863      PMCID: PMC1457901     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Age-dependent variations of antibody avidity.

Authors:  G Doria; G D'Agostaro; A Poretti
Journal:  Immunology       Date:  1978-10       Impact factor: 7.397

2.  Effector cells which mediate antibody-dependent cell-mediated cytotoxicity. II. Ontogeny of effector activity in murine spleen.

Authors:  S B Pollack; D S Kraft
Journal:  Cell Immunol       Date:  1977-11       Impact factor: 4.868

3.  Immune reactivity during aging. I. T-helper dependent and independent antibody responses to different antigens, in vivo and in vitro.

Authors:  D Friedman; A Globerson
Journal:  Mech Ageing Dev       Date:  1978-04       Impact factor: 5.432

4.  Association of autoimmunity, immunodeficiency and aging in man, rabbits, and mice.

Authors:  R A Good; E Yunis
Journal:  Fed Proc       Date:  1974-09

5.  Thymosin and the immunopathology of aging.

Authors:  A L Goldstein; J A Hooper; R S Schulof; G H Cohen; G B Thurman; M C McDaniel; A White; M Dardenne
Journal:  Fed Proc       Date:  1974-09

6.  Lifespan and incidence of cancer and other diseases in selected long-lived inbred mice and their F 1 hybrids.

Authors:  G S Smith; R L Walford; M R Mickey
Journal:  J Natl Cancer Inst       Date:  1973-05       Impact factor: 13.506

Review 7.  Immunologicc activity of the aged.

Authors:  T Makinodan; E H Perkins; M G Chen
Journal:  Adv Gerontol Res       Date:  1971

8.  Possible immune origin of age-related pathological changes in long-lived mice.

Authors:  C P Peter
Journal:  J Gerontol       Date:  1973-07

9.  Autoimmunity in aged mice. Occurrence of autoagglutinating factors in the blood of aged mice with medium and long life-spans.

Authors:  W J Peterson; T Makinodan
Journal:  Clin Exp Immunol       Date:  1972-10       Impact factor: 4.330

10.  K cell cytotoxicity against antibody-coated chicken erythrocytes in tumor-bearing mice: its development with progressively growing tumor and the effect of immunization against the tumor.

Authors:  A Ghaffar; E A Calder; W J Irvine
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

View more
  15 in total

1.  Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases.

Authors:  F Abe; G Alvord; M Koyama; A Matsuda; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Restoration of E-rosette formation by bestatin in patients with bladder cancer.

Authors:  H Yokoyama; T Umeda; K Kobayashi; H Akaza; T Niijima
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

3.  Captopril(SQ 14,225): in vitro and in vivo influence on the proliferative response of rat lymphocytes.

Authors:  L Binderup; E Bramm; E Arrigoni-Martelli
Journal:  Experientia       Date:  1982-03-15

4.  Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults.

Authors:  K Ota; S Kurita; K Yamada; T Masaoka; Y Uzuka; N Ogawa
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.

Authors:  H Blomgren; I Näslund; P L Esposti; L Johansen; O Aaskoven
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice.

Authors:  F Abe; A Matsuda; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Stimulation of cell-mediated immunity by bestatin correlates with reduction of bacterial persistence in experimental chronic Salmonella typhimurium infection.

Authors:  G Dickneite; F Kaspereit; H H Sedlacek
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

8.  Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin).

Authors:  J Yoneda; I Saiki; H Fujii; F Abe; Y Kojima; I Azuma
Journal:  Clin Exp Metastasis       Date:  1992-01       Impact factor: 5.150

9.  Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.

Authors:  F Abe; M Schneider; P L Black; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells.

Authors:  Reishi Toshiyama; Masamitsu Konno; Hidetoshi Eguchi; Hiroyasu Takemoto; Takehiro Noda; Ayumu Asai; Jun Koseki; Naotsugu Haraguchi; Yuji Ueda; Katsunori Matsushita; Kei Asukai; Tomofumi Ohashi; Yoshifumi Iwagami; Daisaku Yamada; Daisuke Sakai; Tadafumi Asaoka; Toshihiro Kudo; Koichi Kawamoto; Kunihito Gotoh; Shogo Kobayashi; Taroh Satoh; Yuichiro Doki; Nobuhiro Nishiyama; Masaki Mori; Hideshi Ishii
Journal:  Oncogene       Date:  2018-08-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.